Navigation Links
Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Date:6/12/2013

BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the United Kingdom) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae. Such early-line use of these agents is indicative of the wider prescribing practices that fuel drug resistance and that have led to higher prevalence of carbapenem-resistant Gram-negative pathogens (GNPs), such as KPC-producing Enterobacteriaceae.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Drug-Resistant Gram-Negative Infections: How Will the Threat of Multidrug-Resistant Gram-Negative Pathogens Impact Market Access for Current and Emerging Antibiotics in the EU5? finds that nearly a third of surveyed physicians prescribe combinations of tigecycline (Pfizer's Tygacil), piperacillin/tazobactam (Pfizer's Zosyn/Tazocin; generics), carbapenems, aminoglycosides and polymyxins early in the treatment algorithm for infections due to multi-drug-resistant (MDR) GNPs, like KPC-producing Enterobacteriaceae or MDR-Pseudomonas. Reflective of physician concern over growing prevalence of these MDR pathogens and limited treatment options currently, over three-quarters of those surveyed anticipate prescribing emerging beta-lactam/beta-lactamase inhibitors CAZ-AVI (Forest/AstraZeneca) and CXA-201 (Cubist), primarily as a carbapenem-sparing therapy and as step therapy for patients failing anti-pseudomonal cephalosporin treatment, respectively.

The report also finds that economic hardships in Europe have translated to increasingly constrained hospital budgets. While the most expensive antibiotics are still cheap compared with biologics used in other therapy areas, interviewed payers warn that increasing patient numbers amid tightening budgets may result in insufficient diagnosis-related group reimbursement rates for overall treatment costs of GNIs, thereby forcing careful budget balancing in busy public institutions. Under pressure to optimize hospital and regional formularies by providing a diverse but cost-effective selection of antibiotics, these payers report that evidence of geographically tailored, cost-efficacy benefit is a key market access lever that will allow them to assess the benefits of novel premium-priced antibiotics against the backdrop of a highly genericized market.

"Interviewed Italian payers believe that even though hospitals are under pressure to reduce costs, they are eager for new therapies that effectively target drug-resistant Gram-negative pathogens," said Decision Resources Analyst Maria Ascano, Ph.D. "Novel therapies with such activity have the potential for rapid regional and hospital formulary inclusion; however manufacturers must be prepared for rigorous health technology assessments across the EU5, and must balance pricing expectations against potential uptake in this highly cost-constrained market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
2. Wound Management Products Market Reaches $15.2 Billion by 2016, Driven by Rising Demand for Bandages and Dressings in Developing World
3. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
4. BidOnHealth.com Offers a Solution to Rising Healthcare Costs
5. Independent Schools Consortium Slams Brakes on Rising Health Care Costs
6. Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
7. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
8. Polymers in Medical Devices: Opportunities Arising and Trends Impacting the Market
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
11. Rising Disease Prevalence Boosts Mexican Healthcare Industry, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):